Dolutegravir cerebrospinal fluid diffusion in HIV-1-infected patients with central nervous system impairment

Abstract

This study aimed to determine dolutegravir cerebrospinal fluid (CSF) diffusion in 13 patients with HIV-related cerebral impairment enrolled in a real-life observational study. Dolutegravir median (range) CSF concentration [9.6 (3.6-22.8) ng/mL] reached CSF therapeutic concentrations whatever the bloodbrain barrier status and diffused in correlation with the albumin quotient (P = .0186).